Advertisement


Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity

2017 San Antonio Breast Cancer Symposium

Advertisement

Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to genetic phenotypes.



Related Videos

Breast Cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract GS2-05).

Breast Cancer

Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial

Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or docetaxel and cyclophosphamide—with or without a year of trastuzumab in women with node-positive or high-risk node-negative disease (Abstract GS1-02).

Breast Cancer

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: the PADMA Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer (Abstract OT3-05-04).

Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, on Immunotherapy in Breast Cancer: Expert Perspective

Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.

Advertisement

Advertisement




Advertisement